Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System.
Della Porta MG
Leukemia. 2017 Mar 21;31(11):2449-2457. doi: 10.1038/leu.2017.88
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study.
Passamonti F
Lancet Haematol. 2020 Aug 13;7(10):e737-e745. doi: 10.1016/S2352-3026(20)30251-9
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
Bernard E
Nat Med. 2020 Aug 3;26(10):1549-1556. doi: 10.1038/s41591-020-1008-z
Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis.
Parenti S
NPJ Precis Oncol. 2021 Feb 4;5(1):4. doi: 10.1038/s41698-021-00144-9
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.
Kuendgen A
Leukemia. 2020 Jun 29;35(3):835-849. doi: 10.1038/s41375-020-0917-7
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes.
Bersanelli M
J Clin Oncol. 2021 Feb 4;39(11):1223-1233. doi: 10.1200/JCO.20.01659
Clinical relevance of clonal hematopoiesis in persons aged ≥80 years.
Rossi M
Blood. 138(21):2093-2105. doi: 10.1182/blood.2021011320
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study.
GenoMed4All consortium
Lancet Haematol. 2022 Nov 24;10(2):e117-e128. doi: 10.1016/S2352-3026(22)00323-4
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Sauta E
J Clin Oncol. 2023 Mar 17;41(15):2827-2842. doi: 10.1200/JCO.22.01784
Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient.
Siddiqui I
J Immunother Cancer. 2016 Apr 19;4:21. doi: 10.1186/s40425-016-0125-1